RecruitingPhase 2NCT06543069
Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM
Studying Malignant peritoneal mesothelioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Principal Investigator
- Yongkun Sun, DoctorCancer Institute and Hospital, Chinese Academy of Medical SciencesCancer
- Intervention
- Sintilimab, Bevacizumab , Pemetrexed , Cisplatin(drug)
- Enrollment
- 28 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2027
Study locations (1)
- Cancer Institute and Hospital,Chinese Academy of Medical Sciences, Beijing, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06543069 on ClinicalTrials.govOther trials for Malignant peritoneal mesothelioma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07330271PTC-Guided Therapy for Peritoneal MesotheliomaBeijing Tsinghua Chang Gung Hospital
- RECRUITINGNCT06581549Immune Microenvironment and Gene Expression Profiling in MesotheliomaIstituto Oncologico Veneto IRCCS
- RECRUITINGPHASE2NCT06057935A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal MesotheliomaMemorial Sloan Kettering Cancer Center